Streptococcal Pneumonia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Streptococcal Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions.
Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate vaccination for Streptococcus pneumoniae, the colonization frequency has decreased. Infection typically occurs after the colonization of the oropharynx and nasopharynx of healthy individuals. Inhalation of these colonies causes the infection of the lower airways. Infection typically will not result unless a patient has predisposed risk factors, a bolus of infectious cells, or colonization with a particularly virulent strain of S. pneumoniae. The Streptococcus pneumoniae cell capsule plays a major role in its pathogenesis; it is made up of polysaccharides and surrounds the cell wall. It helps in escaping phagocytosis by preventing the access of granulocytes to the underlying cell wall.
The Streptococcal Pneumonia drugs in development market research report provide comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Streptococcal Pneumonia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 89 molecules, with 79 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Streptococcal Pneumonia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Streptococcal Pneumonia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Streptococcal Pneumonia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ABAC Therapeutics SAAbcombi Biosciences Inc
Abera Bioscience AB
Acurx Pharmaceuticals Inc
Aeolian Biotech Corp
AIM Vaccine Co Ltd
Alopexx Inc
Beijing Huaan Kechuang Biotechnology Co Ltd
Beijing Minhai Biotechnology Co Ltd
Biocidium Biopharmaceuticals Inc
Biological E Ltd
Blue Water Biotech Inc
BravoVax Co Ltd
CanSino Biologics Inc
Chengdu Antkin Biotechnology Co Ltd
Chengdu Institute of Biological Products Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Crestone Inc
Eubiologics Co Ltd
Evoq Nano Inc
Finlay Institute
GigaGen Inc
GPN Vaccines Ltd
Gritvak
GSK plc
Indian Immunologicals Ltd
International Vaccine Institute
Jiangsu Kunli Biopharmaceutical Co Ltd
Karolinska Institute
KBP Biosciences Co Ltd
Lanzhou Institute of Biological Products Co Ltd
LegoChem Biosciences Inc
Matrivax Research & Development Corp
Max Planck Institute of Colloids and Interfaces
Merck & Co Inc
Nanolek
Neoculi Pty Ltd
Northwestern University
Novo Medi Sciences Pvt Ltd
NovoBiotic Pharmaceuticals LLC
Omniose
Panacea Biotec Ltd
Pfizer Inc
Pneumotactix LLC
PnuVax SL Biopharmaceuticals Inc.
ReNewVax Ltd
Serum Institute of India Pvt Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Ruizhi Pharmaceutical Technology Co Ltd
Shionogi & Co Ltd
Sinovac Biotech Ltd
SPbNIIVS FMBA of Russia
Starmab Biology (Suzhou) Co Ltd
Suzhou Weichao Biotechnology Co Ltd
Tergene Biotech Ltd
University of Chicago
University of Sydney
University of Toledo
Vaxcyte Inc
Virometix AG
Wellstat Vaccines LLC
X4 Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Streptococcal Pneumonia reports